Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo.

Holzleitner, Nadine; Günther, Thomas; Beck, Roswitha; Lapa, Constantin; Wester, Hans-Jürgen

Holzleitner, Nadine; Günther, Thomas; Beck, Roswitha; Lapa, Constantin; Wester, Hans-Jürgen.

Afiliação

Holzleitner N; Pharmaceutical Radiochemistry, Technical University of Munich, 85748 Garching, Germany.
Günther T; Pharmaceutical Radiochemistry, Technical University of Munich, 85748 Garching, Germany.
Beck R; Pharmaceutical Radiochemistry, Technical University of Munich, 85748 Garching, Germany.
Lapa C; Nuclear Medicine, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
Wester HJ; Pharmaceutical Radiochemistry, Technical University of Munich, 85748 Garching, Germany.

Pharmaceuticals (Basel) ; 15(12)2022 Nov 25.

Article em En | MEDLINE | ID: mdl-36558917

Palavras-chave

cholecystokinin-2 receptor (CCK-2R); cholecystokinin-B receptor (CCK-BR); medullary thyroid cancer (MTC); minigastrin analogues; radiohybrid; rhCCK

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google